(Total Views: 617)
Posted On: 01/17/2021 7:43:16 PM
Post# of 148902
CDiddy; here is Scott Carr's post from the Facebook CYDY Investors Group. It is by far the best analysis of mortality from other trials:
I’ve been doing research on other mortality trials for Covid-19. The only clinically proven treatment to reduce mortality is corticosteroids. This article, updated in Dec 2020, lists the results from multiple mortality trails for corticosteroids conducted around the world from January-November 2020. The trial conditions, parameters, and data is clearly laid out in the article (with downloadable PDFs available).
There is really no way to create a perfect side-by-side comparison to our CD12 given that each trial is performed under its own circumstances with varying limitations, parameters and human/patient factors, but I think examining other trails where morality is also their endpoint is a worthy exercise, if anything to see how other mortality treatments are faring in their clinical trials. I encourage anyone interested in the Covid-19 trial process to review these outcomes and their information.
Now, what I find very encouraging for the Leronlimab CD12 trial is we know that one week before trial completion, the total deaths was 87. That puts the mortality rate for the trial at 22% (and we don’t know the mortality rate within each arm of the trial yet, but I think we can safely assume LL is faring better than the placebo otherwise the trial would have been halted). The mortality rate could go up, but given the trial was almost complete, and deaths were being reported as they happened, and the midpoint interim was at 45 deaths, I think it will be unlikely that the trial will exceed much more than 90 deaths, provided there are even any more fatalities. That is merely a guess, but it is rooted in logical extrapolation.
There are 10 trials listed in this article. Many have endpoints of mortality at 28 days (like CD12), and some are just measuring progression of conditions, such as escalating to ICU and ventilation, and some trials involve moderate/non-infected patients (which won’t compare to CD12 where every patient was at last severely ill). I will break down the trials into their most relevant data as they compare to CD12.
I don’t think I’ve cracked the DaVinci code here, but this analysis has made me even more bullish on CytoDyn’s Phase 3 Covid-19 trial
I’ve been doing research on other mortality trials for Covid-19. The only clinically proven treatment to reduce mortality is corticosteroids. This article, updated in Dec 2020, lists the results from multiple mortality trails for corticosteroids conducted around the world from January-November 2020. The trial conditions, parameters, and data is clearly laid out in the article (with downloadable PDFs available).
There is really no way to create a perfect side-by-side comparison to our CD12 given that each trial is performed under its own circumstances with varying limitations, parameters and human/patient factors, but I think examining other trails where morality is also their endpoint is a worthy exercise, if anything to see how other mortality treatments are faring in their clinical trials. I encourage anyone interested in the Covid-19 trial process to review these outcomes and their information.
Now, what I find very encouraging for the Leronlimab CD12 trial is we know that one week before trial completion, the total deaths was 87. That puts the mortality rate for the trial at 22% (and we don’t know the mortality rate within each arm of the trial yet, but I think we can safely assume LL is faring better than the placebo otherwise the trial would have been halted). The mortality rate could go up, but given the trial was almost complete, and deaths were being reported as they happened, and the midpoint interim was at 45 deaths, I think it will be unlikely that the trial will exceed much more than 90 deaths, provided there are even any more fatalities. That is merely a guess, but it is rooted in logical extrapolation.
There are 10 trials listed in this article. Many have endpoints of mortality at 28 days (like CD12), and some are just measuring progression of conditions, such as escalating to ICU and ventilation, and some trials involve moderate/non-infected patients (which won’t compare to CD12 where every patient was at last severely ill). I will break down the trials into their most relevant data as they compare to CD12.
I don’t think I’ve cracked the DaVinci code here, but this analysis has made me even more bullish on CytoDyn’s Phase 3 Covid-19 trial
(2)
(0)Scroll down for more posts ▼
